Other Drugs in 2L: Pembrolizumab
Patients were required to have at least 1% PD-L1 expression
detected on the tumour cells or in tumour stroma, as
determined by immunohistochemistry.
After median follow-up of 13 months (range 1–26, IQR 5–23),
an overall response was achieved in seven (
26%
[95% CI 11–
46]) of 27 assessable patients, with three (11% [2–29])
complete and four (15% [4–34]) partial responses.
